Previous studies have also shown that since PD-1 inhibitor does not affect the metabolic phenotype of tumor-infiltrating lymphocytes42, the combination of metabolic reprogramming drugs and PD-1 inhibitor can achieve additive effects. The gene discussed is PDCD1; the disease is neoplasm.